GPSide,
I wonder why Vaxgen did not tell the whole truth in its SEC prospectus. They have written about the wonderful 100 per cent
efficacy of AIDSVAX with monkeys, but they did not tell, that in
these tests only five monkeys were vaccinated. With five monkey one
cannot make any statistics!
They also did not tell anything about the eleven HIV infections
in Phase II.
My understanding is now, that AIDSVAX is still in the very beginning
of experimental tryings with human individuals (Despite phase III !).
They may change the ingredients of AIDSVAX several times in order to get their 30 percent efficacy. And this takes time, time, and even
more time! ...And money, money, and more money. So I would assume
that it it would not be possible to issue AIDSVAX in 2003. It might take a lot longer. And we all will see how often this stock will be
deluted till AIDSVAX is on the market.
Do not understand me wrong: I am not short.
I owe some VXGN stocks. But at the time I bought them,
I have to admit I was a little naive by only reading the
prospectus.
Regards...
---------------
gmhc.org
excerpt:
Studies have demonstrated that this vaccine protects chimpanzees
from infection with HIV. Because chimpanzees can get infected with
HIV but almost never develop AIDS, they are not considered an ideal
"animal model" for testing a human HIV vaccine. Nevertheless, there
was a clear difference in these studies between vaccinated and
unvaccinated chimpanzees: While all the unvaccinated animals got
infected when challenged with HIV, all the vaccinated chimps, two
in one study and three in the other, were protected. (In the first
study, the chimps were challenged using the same HIV strain — IIIB —
that was the basis for the vaccine with which they were vaccinated.
In the second study, the vaccine strain — MN — differed from the
challenge strain, SF2.)
|
